Novel CKD Therapies Proved Cost Effective Across Health Systems

Why It Matters

Demonstrating cost‑effectiveness across diverse health systems supports broader, earlier adoption of nephroprotective therapies, potentially curbing the escalating financial burden of dialysis and improving patient outcomes.

Key Takeaways

• SGLT2 inhibitors improve QALYs and often lower total costs.
• Cost savings vary widely by country due to pricing and reimbursement.
• Advanced CKD stages drive most expenses; delaying dialysis yields biggest savings.
• Finerenone generally cost‑effective; sotagliflozin and sparsentan sensitive to price.

Pulse Analysis

Chronic kidney disease remains a silent epidemic, affecting over 800 million people worldwide and driving a steep rise in health‑care spending. In the United States alone, more than 35 million adults live with CKD, yet nine‑in‑ten are undiagnosed until the disease advances. The most costly component of care is kidney replacement therapy—dialysis and transplantation—where annual expenses can exceed $80,000 per patient. This fiscal pressure has spurred interest in therapies that can slow disease progression, prompting a wave of economic evaluations to quantify their value.

The recent PharmacoEconomics review synthesized 36 cost‑effectiveness studies, revealing that SGLT2 inhibitors such as dapagliflozin, empagliflozin and canagliflozin consistently generate quality‑adjusted life‑year gains and, in many settings, produce net savings. However, the magnitude of economic benefit hinges on local drug pricing, reimbursement policies, and health‑system structures. For example, Dutch models reported savings over $40,000 per patient, while a U.S. analysis projected incremental costs exceeding $100,000 per QALY. Such heterogeneity underscores the importance of tailored pricing negotiations and value‑based contracts to unlock the full potential of these agents.

Policymakers and payers can leverage these findings to prioritize early adoption of cost‑effective nephroprotective drugs, especially for patients approaching stage 3 CKD where cost escalation accelerates. While finerenone shows promise across multiple markets, agents like sotagliflozin and sparsentan demand careful price‑access arrangements to meet conventional thresholds. Notably, the evidence gap in low‑income countries signals a need for more inclusive research and adaptable pricing models. As health systems grapple with rising CKD prevalence, integrating robust economic data into formulary decisions will be crucial for sustaining both fiscal responsibility and patient health.